Navigation Links
Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
Date:6/29/2010

MONT-SAINT-GUIBERT, Belgium, June 29, 2010 /PRNewswire/ -- Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.

Results showed C-Cure to have a very good safety profile with no adverse events related to C-Cure, as assessed by an independent board. The study is also examining a number of measures of efficacy. With three month follow up data in-hand, Cardio3 BioSciences has observed positive and encouraging trends in a number of physiological and clinical parameters. Meaningful differences were seen in ventricular size, ejection fraction and other measures of heart muscle activity in C-Cure treated patients when compared to control and to baseline. Partial data from a paired analysis of patients at six-months follow-up is suggestive of these beneficial trends being reinforced over time. Cardio3 Biosciences intends to publish the study results once the full six month dataset is available and has been analysed.

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "The data so far from our trial is very encouraging. We showed that C-Cure is safe at three months. We also saw positive trends in other measures that suggest that C-Cure, as anticipated from animal model data, is acting on heart muscle in a way that could yield important clinical benefits. We now look forward to seeing the full six-month follow-up data and completing the analysis of the trial."

"With the confidence and experience gained from this trial, we are moving ahead with finalizing the design of our pi
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... team of researchers from South Korea ... plays an important role in accelerating the repair ... experimental mouse model, by promoting blood vessel formation ... tissue.  The research found that the underlying mechanism ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and ... to 100x better detail than the industry standard. ... light microscopy methods, it needed another medium to measure ... frame of reference because it represents the highest standard ... the earliest discovery days of Ultralight Histology was to ...
(Date:5/4/2015)... , May 4, 2015 China Cord Blood ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Meditech"), a Hong Kong listed ... entered into an agreement (the "Agreement") to purchase the ...
(Date:5/4/2015)... --  Tocagen Inc. , a clinical-stage immuno-oncology company, ... investigational studies were presented at the 11 th ... Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section ... Washington, D.C. In addition, Tocagen ... and continues to advance towards initiation of a ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
... Women with below-the-knee ... after endovascular treatment, 88 percent of women avoided amputation compared to 83 percent of ... ... of lower-leg amputation fare even better than men when they have minimally invasive treatment to ...
... ... partnership among 2 leading service providers to the world-wide biopharmaceutical industry. Quintiles, ... for electronic Patient Reported Outcomes (ePRO) solutions and services. , ... Research Triangle Park, N.C., ...
... the divas of the nanoworld. In possession of alluring ... carbon-based cousins. On the plus side, they can ... says Yoke Khin Yap, an associate professor of physics ... charcoal in a barbecue at half of those temperatures," ...
Cached Biology Technology:Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 2Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 3Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development 2Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development 3Harnessing the divas of the nanoworld 2
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... weapon in the arsenal against cancer: Nanoparticles that identify, ... cells alone. Led by Carl Batt, the Liberty ... nanoparticles shaped something like a dumbbell made ... They then attached antibodies, which target a molecule found ...
... of God and the nature of religion, two distinguished ... in evolutionary biology with a focus on brain science, ... Tiger and pioneering neuroscientist Michael McGuire elucidate perennial questions ... arise? What is its source? And why does every ...
... breakthrough treatments for the most common cancers could soon come ... At the ESMO Conference on Sarcoma and GIST, to ... 2010, researchers and some of the world,s leading experts will ... found in muscle, blood vessels, deep skin tissues, nerves and ...
Cached Biology News:Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Which came first: Religion or the brain? 2Spotlight on rare tumors in hunt for new cancer treatments 2
hypertension-related calcium-regulated gene, mRNA...
Human SOST Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Biology Products: